Takeda Pharmaceutical Company announced its complete withdrawal from cell therapy research and development, marking a strategic portfolio reprioritization. The company is seeking external partnerships to advance research and clinic-ready programs but currently has no active clinical trials in the space. This move follows recent layoffs and program cutbacks amid broader restructuring driven by patent expirations and profit pressures. Takeda will redirect investment toward biologics, small molecules, and antibody-drug conjugates with near-term transformative potential. The $394 million impairment charge associated with discontinued cell therapy assets reflects this significant shift away from a once prioritized scientific focus.